WO2024141995 - COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS AND ANTI-VEGFR-2 ANTIBODIES
National phase entry:
Publication Number
WO/2024/141995
Publication Date
04.07.2024
International Application No.
PCT/IB2023/063354
International Filing Date
28.12.2023
Title **
[English]
COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS AND ANTI-VEGFR-2 ANTIBODIES
[French]
COMPOSITIONS, SYSTÈMES ET MÉTHODES DE TRAITEMENT DU CANCER À L'AIDE DE CHAMPS DE TRAITEMENT DE TUMEUR ET D'ANTICORPS ANTI-VEGFR-2
Applicants **
NOVOCURE GMBH
Neuhofstrasse 21
6340 Baar, CH
Inventors
VOLOSHIN-SELA, Tali
Topaz Building, 4th Floor, MATAM Center
P.O. Box 15022, Sha'ar HaCarmel
31905 Haifa, IL
KLEIN-GOLDBERG, Anat
Topaz Building, 4th Floor, MATAM Center
P.O. Box 15022, Sha'ar HaCarmel
31905 Haifa, IL
AVIGDOR, Lilach
Topaz Building, 4th Floor, MATAM Center
P.O. Box 15022, Sha'ar HaCarmel
31905 Haifa, IL
Priority Data
63/477,396
28.12.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1167 | |
| EPO | Filing, Examination | 4713 | |
| Japan | Filing | 588 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 3310 |
Total: 10352 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Compositions, systems, and methods for reducing viability of cancer cells and treating cancer, as well as preventing an increase of volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating field in combination with administration of at least one composition comprising at least one antibody that specifically binds to a vascular endothelial growth factor receptor-2 (anti-VEGFR-2 antibody).[French]
Des compositions, des systèmes et des méthodes pour réduire la viabilité de cellules cancéreuses et traiter le cancer, ainsi que pour prévenir une augmentation du volume d'une tumeur présente dans le corps d'un patient vivant sont divulgués. Les systèmes et les procédés impliquent l'application d'un champ alternatif en association avec l'administration d'au moins une composition comprenant au moins un anticorps qui se lie spécifiquement à un récepteur 2 du facteur de croissance endothéliale vasculaire (anticorps anti-VEGFR-2).